Francesco Graziano

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini et al. · British Journal of Cancer · 2009 · 561 citations · Full text

Medicine, Genetics, Oncology +17

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

Fotios Loupakis, Luca Emanuele Pollina, I. Stasi et al. · Journal of Clinical Oncology · 2009 · 404 citations · Full text

Medicine, Oncology, Pharmacology +17

Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study.

Giammaria Fiorentini, Camillo Aliberti, Massimo Tilli et al. · PubMed · 2012 · 331 citations

Medicine, Oncology, Pharmacology +17

Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition

Gabrielle S. Wong, Jin Zhou, Jie Bin Liu et al. · Nature Medicine · 2018 · 279 citations · Full text

Medicine, Cancer Biology, Oncology +11

Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy

Annamaria Ruzzo, Francesco Graziano, Fotios Loupakis et al. · Journal of Clinical Oncology · 2007 · 266 citations · Full text

Medicine, Oncology, Pharmacology +17